Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-0214
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
GDC-0214 is a potent, selective small molecule inhibitor of Janus kinase 1 (JAK1) developed for inhaled administration as a potential treatment for asthma. The drug was designed to achieve targeted JAK1 inhibition in the lungs while minimizing systemic exposure and associated toxicity. By inhibiting JAK1, GDC-0214 blocks signaling pathways mediated by cytokines such as interleukin (IL)-4 and IL-13 that are implicated in the pathogenesis of asthma. Clinical studies demonstrated dose-dependent reductions in fractional exhaled nitric oxide (FeNO), a biomarker of airway inflammation dependent on JAK1-mediated pathways. The drug was developed by Genentech (a subsidiary of Roche) but its development for asthma has been discontinued after phase I trials.
- Other names
- GDC0214GDC-0214GDC 0214
02
Targets
Beyond the preview
Go deeper on GDC-0214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-0214.